Formed in 2005, the Sanford Consortium is a nonprofit organization that marshals the intellectual resources of five world-leaders in life sciences research: the Sanford-Burnham Medical Research Institute, the Salk Institute for Biological Studies, The Scripps Research Institute, the University of California, San Diego and the La Jolla Institute for Allergy & Immunology. Using the collective strength of its members, the Consortium’s research program is focused on developing tools and technologies to hasten the pace of stem cell research progress and to discover and develop diagnostics, therapies and cures to relieve human suffering from chronic disease and injury. The Consortium was originally assembled as the San Diego Consortium for Regenerative Medicine, but renamed in September 2008 after a naming donation from T. Denny Sanford.
The California Institute for Regenerative Medicine is accelerating the development of new therapies for chronic disease and injury by funding stem cell research programs throughout California. We were established in 2004 after Californians passed Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 110 members and is the leading global advocacy organization in this field. In March 2012, ARM played a pivotal role in launching a sister organization in Europe — the Alliance for Advanced Therapies.